Discover and read the best of Twitter Threads about #HPBCSM
Most recents (4)
#GI21 time for another #Tweetorial🧵 on
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA
in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM
~3️⃣0️⃣% actionable findings
Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs
🧵2️⃣ #GI21
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.
We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾
🧵3️⃣ #GI21
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
We often don’t think of #ctDNA based platforms to be as sensitive for detecting fusions; when present it is real & an actionable finding.
Interestingly we found #FGFR🧬fusions
🩸LIQUID>>TISSUE🔬
💭 maybe because of selection bias. #ctDNA filling the void. #OncoAlert
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
For #GIJournalClub – we will discussing the @NEJM article:
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Background:
- Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
- Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
- Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
- Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
Background – drug mechanisms:
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
Picture credit: nature.com/articles/s4157…
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
Picture credit: nature.com/articles/s4157…
For #GIJournalClub – we will discussing the @NEJM article:
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Background:
✅ Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
✅ Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
✅ Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
✅ Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
Background – drug mechanisms:
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
[Picture credit: nature.com/articles/s4157…]
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
[Picture credit: nature.com/articles/s4157…]
